Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Vliv doplňování Akkermansia Muciniphila a Berberinu na inzulinovou senzitivitu u pracovníků nočních směn (Shift2Health)

10. listopadu 2026 aktualizováno: FH Joanneum Gesellschaft mbH

Účinky doplňování Akkermansia Muciniphila a Berberinu na inzulinovou senzitivitu u pracovníků na noční směny: dvojitě zaslepená, randomizovaná, placebem kontrolovaná, křížová studie v rámci projektu Shift2Health

Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns. These behavioral and physiological disturbances impair glucose metabolism and are further influenced by the gut microbiota. In particular, the bacterium Akkermansia muciniphila has been linked to improved metabolic health, including enhanced insulin sensitivity, lipid regulation, and maintenance of intestinal barrier integrity. Berberine, a bioactive plant-derived compound, has demonstrated metabolic benefits, including upregulation of A. muciniphila, improvement of insulin sensitivity, and modulation of lipid metabolism.

Together, these complementary mechanisms suggest that combined A. muciniphila supplementation and berberine administration may synergistically improve metabolic health in shift workers by targeting gut microbiota composition and circadian-regulated metabolic pathways.

Based on this rationale, a double-blind, randomized, placebo-controlled, crossover study is being conducted in 200 night-shift workers from healthcare and industrial sectors in Austria and Denmark. Participants are stratified by age, sex, and work sector and randomly assigned to intervention sequences. Each participant receives either the combined supplement or placebo for 12 weeks, followed by a four-week washout, after which the alternate intervention is administered for another 12 weeks, with a total participation of 28 weeks.

Assessments are performed at four study visits and include anthropometry, body composition, blood pressure, and collection of blood, urine, and feces. Participants complete validated questionnaires on dietary intake, lifestyle, work schedules, and general health to monitor behavioral patterns throughout the study. Dietary intake is recorded for four days prior to each sampling visit in consideration of shift schedules. Sleep duration and quality are monitored via diaries and actigraphy and aligned with dietary records. Circadian variation is minimized by standardizing sampling times and implementing a fasting and synchronization period prior to visits.

The primary outcome is insulin sensitivity, measured by HOMA-IR. Secondary exploratory outcomes include gut microbiota composition and diversity, biomarkers of intestinal permeability and inflammation, lipid profiles, body composition, sleep quality, and dietary behavior.

These measures collectively provide a comprehensive evaluation of the metabolic, microbiome, and circadian effects of combined A. muciniphila and berberine supplementation in night-shift workers.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

200

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Styria
      • Graz, Styria, Rakousko, 8020
        • Nábor
        • FH JOANNEUM University of Applied Sciences
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

21 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Health care or industrial shift worker
  • Employed or self-employed working ≥ 24 h/week
  • Current night shift work (night shift defined as a work schedule that includes at least 3 hours of work between 00:00 and 5:00) with at least 2 consecutive nights/month
  • Night shift work duration > 3 years
  • 4 or more night shifts/month

Exclusion Criteria:

  • BMI of 40 kg/m² or higher
  • Pregnancy or planned pregnancy within 6 months of enrolment or breastfeeding women
  • Bariatric surgery
  • Surgery in the 3 months prior to the study or planned surgery in the next 6 months that, in the opinion of the investigators, could potentially affect the outcome of the study
  • Diagnosed diabetes type 1 or type 2
  • Uncontrolled thyroid disease (confirmed by clinically significant abnormal TSH/T4 levels without stable medication for more than 3 months)
  • Chronic diseases (renal failure, active hepatitis, liver cirrhosis, myocardial infarction within the last 2 years, stroke, chronic obstructive pulmonary disease or cancer)
  • Immunodeficiency syndrome, active autoimmune or autoinflammatory disease (e.g. multiple sclerosis, lupus, rheumatoid arthritis), inflammatory bowel disease (e.g. IBS or ulcerative colitis) and acute episodes of atopic diseases (atopic dermatitis, asthma, type 1 allergies such as hay fever). Grave's disease, Hashimoto thyroiditis, Celiac disease, sarcoidosis, Lichen planus, are allowed, if well treated and stable
  • Regular intake of anticoagulants
  • Known allergy to any inactive or active ingredients in the study products
  • Participation in other clinical intervention trials during the study
  • Current or planned participation in a weight loss program (including intermittent fasting), extreme diet, or vigorous exercise (e.g., running, fast cycling, swimming laps, or playing intense sports that quickly raise your heart rate)

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Základní věda
  • Přidělení: Randomizované
  • Intervenční model: Crossover Assignment
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: AB Group

Participants will first receive Verum (A) for 3 months. After a 4-week washout period, they will receive Placebo (B) for 3 months.

1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day.

1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day.

Experimentální: BA Group

Participants will first receive Placbo (B) for 3 months. After a 4-week washout period, they will receive Verum (A) for 3 months.

1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day.

1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change of 3-months supplementation with A. muciniphila and berberine on insulin resistance using HOMA-IR compared to placebo
Časové okno: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Homeostasis Model Assessment of Insulin Resistance, calculated as (fasting insulin (μU/ml) x fasting glucose (mmol/l)) / 22.5, will be assessed to calculate the change between baseline and endpoint in the two periods

At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in gut microbiom composition between the baseline and endpoint change in the two periods
Časové okno: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Gene sequencing of the 16S rRNA is performed on the stool samples to compare microbiota diversity and relative abundance

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in FABPi between the baseline and endpoint change in the two periods
Časové okno: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Measurement of FABP intestinal (FABPi) in blood (pg/mL)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in zonulin between the baseline and endpoint change in the two periods
Časové okno: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Measurement of zonulin in blood (ng/mL)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in LPB between the baseline and endpoint change in the two periods
Časové okno: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Measurement of lipopolysaccharide-binding protein (LPB) in blood (pg/mL)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in CRP between the baseline and endpoint change in the two periods
Časové okno: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Analysis of high-sensitive C-reactive protein (hs-CRP, mg/L) in blood

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in stool short-chain fatty acids (SCFA) between the baseline and endpoint change in the two periods
Časové okno: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

SCFA will be extracted and quantitatively analysed by GC-MS (µmol/g)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in blood lipid profile and cardiovascular markers between the baseline and endpoint change in the two periods
Časové okno: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Measurement of cholesterol (mmol/L), low-density lipoprotein cholesterol (LDL-C, mmol/L), high-density lipoprotein (HDL-C, mmol/L), and triglyceride levels (TG, mmol/L) in blood

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in blood pressure between the baseline and endpoint change in the two periods
Časové okno: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Systolic BP (mmHG) and diastolic BP (mmHG)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in melatonin between the baseline and endpoint change in the two periods
Časové okno: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

6-sulfatoxymelatonin in urine (µg/L)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in BMI between the baseline and endpoint change in the two periods
Časové okno: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Body mass index (BMI)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in body composition between the baseline and endpoint change in the two periods
Časové okno: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Bioelectrical Impedance Analysis (BIA)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in metabolomics at the end of the two periods
Časové okno: At the beginning and the end of each intervention period (week 12, week 28)

Metabolomic profiles obtained with LC-MS/MS

At the beginning and the end of each intervention period (week 12, week 28)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

20. ledna 2026

Primární dokončení (Odhadovaný)

1. října 2027

Dokončení studie (Odhadovaný)

1. února 2028

Termíny zápisu do studia

První předloženo

27. ledna 2026

První předloženo, které splnilo kritéria kontroly kvality

23. února 2026

První zveřejněno (Aktuální)

27. února 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

16. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

10. listopadu 2026

Naposledy ověřeno

1. ledna 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 1306/2025
  • 101080788 (Jiné číslo grantu/financování: Horizon Europe)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .